This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide at pH 8.15 (formulation 4) and liraglutide at pH 7.7 (formulation 3).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
22
One single dose of 6.25 mg/mL administered subcutaneously
One single dose of 6.0 mg/mL administered subcutaneously
Unnamed facility
Lund, Sweden
Area under the curve (0-t)
Cmax, maximum concentration
Area under the curve
tmax, time to reach Cmax
t½, terminal half-life
Terminal elimination rate constant
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.